Effects on arterial receptors of ergot derivatives used in migraine.
D000818:Animals; D002417:Cattle; D004087:Dihydroergotamine / Q000494:pharmacology; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004879:Ergotamines / Q000494:pharmacology*; D006801:Humans; D066298:In Vitro Techniques; D008881:Migraine Disorders / Q000188:drug therapy*; D009131:Muscle, Smooth, Vascular / Q000187:drug effects; D009638:Norepinephrine / Q000494:pharmacology; D010646:Phentolamine / Q000494:pharmacology; D010918:Pizotyline / Q000494:pharmacology; D011942:Receptors, Adrenergic, alpha / Q000187:drug effects; D011985:Receptors, Serotonin / Q000187:drug effects*; D012701:Serotonin / Q000494:pharmacology; D012702:Serotonin Antagonists / Q000494:pharmacology; D014662:Vasoconstrictor Agents; D014666:Vasomotor System / Q000187:drug effects*
D004879:Ergotamines; D011942:Receptors, Adrenergic, alpha; D011985:Receptors, Serotonin; D012702:Serotonin Antagonists; D014662:Vasoconstrictor Agents; D010918:Pizotyline; D012701:Serotonin; D004087:Dihydroergotamine; D009638:Norepinephrine; D010646:Phentolamine